Please login to the form below

Not currently logged in
Email:
Password:

Aliqopa

This page shows the latest Aliqopa news and features for those working in and with pharma, biotech and healthcare.

Novartis claims a rare win at ESMO for PI3K inhibitor class

Novartis claims a rare win at ESMO for PI3K inhibitor class

Zydelig is among the existing PI3K inhibitors on the market. Three PI3K inhibitors have been approved for blood cancers – namely Gilead Sciences’  Zydelig (idelalisib), Bayer’s Aliqopa (copanlisib) and most recently

Latest news

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
emotive.

emotive. is an award-winning healthcare communications agency working with leading global and EMEA companies in life sciences including medical device...

Latest intelligence

Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...

Infographics